pH-Sensitive nano-systems for drug delivery in cancer therapy

Liu, Juan; Huang, Yongfeng; Kumar, Anil; Tan, Aaron; Jin, Shubin; Mozhi, Anbu; Liang, Xing‐Jie

doi:10.1016/j.biotechadv.2013.11.009

Cited by 964 publications

(538 citation statements)

References 174 publications

Supporting

Mentioning

536

Contrasting

Unclassified

Order By: Relevance

“…This increases activation of acid-labile molecules for anticancer therapy with some tumor specificity. This strategy is being vigorously tested in the context of acid labile nanoparticles, targeting agents and prodrugs like C2-docetaxel [21,22]. This study introduces the application of the acid labile chemistry of silyl ethers tagged chemotherapeutics as a targeting agent for intracranial tumors.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Pharmacokinetics of a Modified acid-labile docetaxel-PRINT ^® Nanoparticle Formulation Against non-small-cell Lung Cancer Brain Metastases

Sambade¹,

Deal²,

Schorzman

et al. 2016

Nanomedicine (Lond.)

View full text Add to dashboard Cite

Aim: Particle Replication in Nonwetting Templates (PRINT ® ) PLGA nanoparticles of docetaxel and acid-labile C2-dimethyl-Si-Docetaxel were evaluated with small molecule docetaxel as treatments for non-small-cell lung cancer brain metastases. Materials & methods: Pharmacokinetics, survival, tumor growth and mice weight change were efficacy measures against intracranial A549 tumors in nude mice. Treatments were administered by intravenous injection. Results: Intracranial tumor concentrations of PRINT-docetaxel and PRINT-C2-docetaxel were 13-and sevenfold greater, respectively, than SM-docetaxel. C2-docetaxel conversion to docetaxel was threefold higher in intracranial tumor as compared with nontumor tissues. PRINT-C2-docetaxel increased median survival by 35% with less toxicity as compared with other treatments. Conclusion: The decreased toxicity of the PRINT-C2-docetaxel improved treatment efficacy against non-small-cell lung cancer brain metastasis. PLGA nanoparticleLung cancer, 80% comprised of non-smallcell lung cancer (NSCLC), is one of the leading causes of cancer worldwide and the USA [1][2][3]. Lung cancer is the most common primary tumor responsible for brain metastases [19]. Among those diagnosed with NSCLC, 20-50% of patients will develop metastatic brain disease [2], 10% with brain metastases at initial diagnosis [4] and another 30% later in their disease course following standard therapies.Despite multimodality therapy with combinations of surgery, radiation therapy and chemotherapy, median survival remains less than one year for NSCLC brain metastatic patients [1,2]. NSCLC brain metastases are generally nonresponsive to first-line, single agent platinum-based chemotherapy [2,5]. Docetaxel (Taxotere ® ) is a standard second line systemic chemotherapy for NSCLC brain metastases [2]. As brain metastasis recurrence is common among patients with advanced NSCLC, optimizing the passage of anticancer agents across the blood-brain barrier, increasing chemotherapeutic concentrations in intracranial and extracranial tumors and decreasing systemic toxicities are important considerations to improve treatment of this disease. Newer delivery techniques, like nanoparticles and carrier-mediated technologies, have illustrated these advantages in the setting of intracranial cancer [6][7][8][9][10]. Clinically, activity of nanoparticle-based systemic therapy has been illustrated in the setting of breast cancer brain metastases, another solid tumor type where brain metastasis recurrence is common [11].While several studies have shown the superiority of nanoparticle anticancer agents in intracranial malignancies over standard formulations, the mechanism underlying this

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and Pharmacokinetics of a Modified acid-labile docetaxel-PRINT ^® Nanoparticle Formulation Against non-small-cell Lung Cancer Brain Metastases

Sambade¹,

Deal²,

Schorzman

et al. 2016

Nanomedicine (Lond.)

View full text Add to dashboard Cite

show abstract

“…pH-Triggered Release: Acid-labile chemical bonds that are stable in the bloodstream (pH 7.4) but upon endocytic internalization are cleaved in the slightly acidic late endosomal (pH 5-6) and lysosomal (pH 4-5) environments, have been used to promote endolysosomal release. [30][31][32] Among the different pH sensitive linkers, which are available, such as acetal/ketal, [28][29][30][31][32][33][34][35][36][37][38][39][40][41] ortho ester, [30][31][32][42][43][44] imine, [30][31][32]36,[45][46][47][48] oxime, [28,31,36,[49][50][51] and maleic acid amide derivatives, [29,30,32,41,[52][53][54] the hydrazone linker [28][29][30][31]<...>…”

Section: Endolysosomal Releasementioning

confidence: 99%

“…Endolysosomal release pH Endosomes/ lysosomes Acetal/ketal [28][29][30][31][32]36] Linear polymers [33][34][35] Micelles [37,41] Polymersomes [38,40] Nanoparticles [39] Ortho ester [30][31][32] Micelles [42,43] Polymersomes [44] Imine [30][31][32]36] Micelles [45][46][47][48] Oxime [28,31,36] Nanoparticles [49] Micelles [50,51] Maleic acid amide derivatives [29,30,32] Micelles [41,52,54] Nanoparticles [53] Hydrazone [28][29][30][31][32]36] Linear polymers [55][56]…”

Section: Functionality Examplesmentioning

confidence: 99%

Controlling and Monitoring Intracellular Delivery of Anticancer Polymer Nanomedicines

Battistella

Klok

2017

Macromolecular Bioscience

View full text Add to dashboard Cite

Polymer nanomedicines are very attractive to improve the delivery of chemotherapeutics. Polymer conjugates and other polymer‐based nanocarriers allow to increase plasma half‐life and drug bioavailability and can also be guided toward tumors using passive and active targeting strategies. Since many chemotherapeutics act on targets that are located in well‐defined subcellular compartments, other important factors that contribute to an efficient therapy include cellular internalization and subsequent intracellular trafficking of the polymer nanomedicines and/or its payload to the appropriate organelle in the cytoplasm. This article provides an overview of the different approaches that have been developed to control intracellular delivery of polymer nanomedicines and discusses the different techniques that can be used to monitor these processes.

show abstract

“…Because of these virtues associated with pH-sensitive carriers, several groups have reported on some original pH sensitive systems [29][30][31][32]. To date, one of the most effective systems is lipid nano particles (LNPs), which consist of a hydrophilic moiety containing a tertiary amino group, a linker and two hydrophobic dialkene groups [33].…”

Section: Sirna Delivery To Tumors and The Tumor Vasculature Using A Pmentioning

confidence: 99%

“Programmed packaging” for gene delivery

Hyodo

Sakurai

Akita

et al. 2014

Journal of Controlled Release

View full text Add to dashboard Cite

We report on the development of a Multifunctional Envelope-type Nano Device (MEND) based on our packaging concept "Programmed Packaging" to control not only intracellular trafficking but also the biodistribution of encapsulated compounds such as nucleic acids/proteins/peptides. Our strategy for achieving this is based on molecular mechanisms of cell biology such as endocytosis, vesicular trafficking, etc. In this review, we summarize the concept of programmed packaging and discuss some of our recent successful examples of using MENDs. Systematic evolution of ligands by exponential enrichment (SELEX) was applied as a new methodology for identifying a new ligand toward cell or mitochondria. The delivery of siRNA to tumors and the tumor vasculature was achieved using pH sensitive lipid (YSK05), which was newly designed and optimized under in vivo conditions. The efficient delivery of pDNA to immune cells such as dendritic cells has also been developed using the KALA ligand, which can be a breakthrough technology for DNA vaccine. Finally, ss-cleavable and pH-activated lipid-like surfactant (ssPalm) which is a lipid like material with pH-activatable and SS-cleavable properties is also introduced as a proof of our concept.

show abstract

pH-Sensitive nano-systems for drug delivery in cancer therapy

Cited by 964 publications

References 174 publications

Efficacy and Pharmacokinetics of a Modified acid-labile docetaxel-PRINT ^® Nanoparticle Formulation Against non-small-cell Lung Cancer Brain Metastases

Efficacy and Pharmacokinetics of a Modified acid-labile docetaxel-PRINT ^® Nanoparticle Formulation Against non-small-cell Lung Cancer Brain Metastases

Controlling and Monitoring Intracellular Delivery of Anticancer Polymer Nanomedicines

“Programmed packaging” for gene delivery

Contact Info

Product

Resources

About

pH-Sensitive nano-systems for drug delivery in cancer therapy

Cited by 964 publications

References 174 publications

Efficacy and Pharmacokinetics of a Modified acid-labile docetaxel-PRINT ® Nanoparticle Formulation Against non-small-cell Lung Cancer Brain Metastases

Efficacy and Pharmacokinetics of a Modified acid-labile docetaxel-PRINT ® Nanoparticle Formulation Against non-small-cell Lung Cancer Brain Metastases

Controlling and Monitoring Intracellular Delivery of Anticancer Polymer Nanomedicines

“Programmed packaging” for gene delivery

Contact Info

Product

Resources

About

Efficacy and Pharmacokinetics of a Modified acid-labile docetaxel-PRINT ^® Nanoparticle Formulation Against non-small-cell Lung Cancer Brain Metastases

Efficacy and Pharmacokinetics of a Modified acid-labile docetaxel-PRINT ^® Nanoparticle Formulation Against non-small-cell Lung Cancer Brain Metastases